by jtcir-auto | May 17, 2021 | Press Releases
– Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the treatment of ALSCHARLESTON, S.C., May 17, 2021 —...
by jtcir-auto | May 13, 2021 | Press Releases
-Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency (“EMA”) in the Company’s Pediatric Investigation Plan (“PIP”) – Patient enrollment on track to start this quarter-...
by jtcir-auto | May 13, 2021 | Press Releases
-Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency (“EMA”) in the Company’s Pediatric Investigation Plan (“PIP”) – Patient enrollment on track to start this quarter-...
by jtcir-auto | May 10, 2021 | Press Releases
– Live video webcast with CEO, Dr. Klaus Paulini, onMonday, May 17, 2021 at 8:45 AM ETCHARLESTON, S.C., May 10, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company...
by jtcir-auto | May 10, 2021 | Press Releases
– Live video webcast with CEO, Dr. Klaus Paulini, onMonday, May 17, 2021 at 8:45 AM ETCHARLESTON, S.C., May 10, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company...
by jtcir-auto | May 6, 2021 | Press Releases
-In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical...